Market Place
Sourcing Support
Even after Prometheus, Acceleron deals, Merck primed for M&A
01 Feb 2024 //
FIERCE PHARMA
Merck unwraps full PIII data on the centerpiece from its $11.5B Acceleron buyout
07 Mar 2023 //
ENDPTS
Early look at how Merck & Co.’s sotatercept could impact PAH space
17 Oct 2022 //
FIRSTWORLDPHARMA
Merck nails phase 3 sotatercept win a year after acquiring it
11 Oct 2022 //
FIERCEBIOTECH
Celgene, Acceleron alum Backstrom tapped to lead Scholar Rock
20 Sep 2022 //
FIERCEBIOTECH
FDA warns small biotech Ocugen of potential $10K fines for failing
25 Apr 2022 //
ENDPTS
Merck’s Acceleron Integration To Take Out 143 Jobs in Cambridge, MA
31 Mar 2022 //
BIOSPACE
Merck fights off Acceleron`s activist investors
22 Nov 2021 //
FIERCEPHARMA
Merck Completes Tender Offer to Acquire Acceleron Pharma
20 Nov 2021 //
FIRSTWORLFPHARMA
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
19 Nov 2021 //
BUSINESSWIRE
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period
17 Nov 2021 //
BUSINESSWIRE
Avoro Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer
17 Nov 2021 //
BUSINESSWIRE
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders
09 Nov 2021 //
BUSINESSWIRE
Another Acceleron investor challenges Merck deal
04 Nov 2021 //
FIERCEPHARMA
Merck refiles Acceleron deal with the FTC
02 Nov 2021 //
FIERCEPHARMA
Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act
29 Oct 2021 //
BUSINESSWIRE
Merck set to deploy millions of Covid antiviral pills if regulators approve: CEO
28 Oct 2021 //
CNBC
Ahead of closing $11.5B Acceleron buyout, Merck is on the hunt for more deals
28 Oct 2021 //
ENDPTS
BMS Buyout Rumors Send Canadian Biopharma’s Stock Soaring
25 Oct 2021 //
BIOSPACE
BMS, after weighing Acceleron buy, now eyes Aurinia: Bloomberg
23 Oct 2021 //
FIERCEPHARMA
Activist investor asks Merck to double Acceleron offer
22 Oct 2021 //
FIERCEPHARMA
Hedge fund jumps in with Avoro activists to derail Merck`s $11B Acceleron buyout
21 Oct 2021 //
ENDPTS
Bristol-Myers Plans to Exit Acceleron Stake With Merck Deal
20 Oct 2021 //
BNNBLOOMBRG
Merck started its Acceleron pursuit at $10.2B, ended at $11.5
12 Oct 2021 //
FIERCEPHARMA
Biogen, Mirati, mRNA players on Merck`s M&A shortlist: FT
06 Oct 2021 //
FIERCEPHARMA
Activist investor revolts against Acceleron`s $11.5B sale
02 Oct 2021 //
FIERCEPHARMA
Acceleron falls below averages, but Avoro looks opportunistic
01 Oct 2021 //
EVALUATE
Unexpected win opens the way to an oral Covid antiviral
01 Oct 2021 //
EVALUATE
Merck buys Acceleron for $11.5B, dowplays antitrust threat
01 Oct 2021 //
FIERCEPHARMA
Merck & Co justifies paying up for Acceleron
30 Sep 2021 //
EVALUATE
Merck`s reported $11B Acceleron buy could face antitrust hurdles
28 Sep 2021 //
FIERCEPHARMA
Merck emerges as lead bidder in potential Acceleron buyout — report
27 Sep 2021 //
ENDPTS
Mystery suitor lines up $11B Acceleron acquisition: report
27 Sep 2021 //
FIERCEBIOTECH
Rumors suggest that Acceleron is in advanced buyout talks: Report
25 Sep 2021 //
ENDPTS
Acceleron Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
BUSINESSWIRE
Acceleron Announces Second Quarter 2021 REBLOZYL® Net Sales
29 Jul 2021 //
BUSINESSWIRE
Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021
26 Jul 2021 //
BUSINESSWIRE
BMS, Acceleron’s Reblozyl shows new improvements for beta thalassemia patients
10 Jun 2021 //
PMLIVE
Acceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021
08 Jun 2021 //
BUSINESSWIRE
Acceleron, under threat of fines, reports out a negative study
26 May 2021 //
RAPS
Acceleron Presents Preliminary Data from the SPECTRA Ph 2 Trial of Sotatercept
18 May 2021 //
BIOSPACE
Acceleron Presents Interim Results from the Open-label Extension the PULSAR Ph2
18 May 2021 //
BUSINESSWIRE
Acceleron Presents Preliminary Data from the SPECTRA Ph2 Trial of Sotatercept
18 May 2021 //
BUSINESSWIRE
Acceleron to Host Conference Call and Webcast to Review Clinical Trial Updates
11 May 2021 //
BUSINESSWIRE
Acceleron to Host Conference Call and Webcast to Review Clinical Trial Updates
11 May 2021 //
BUSINESSWIRE
FDA Gets Tough on Sponsors Not Reporting Clinical Trial Results
07 May 2021 //
PHARMTECH
FDA gives first citation to biotech for failure to report clinical trial details
30 Apr 2021 //
BIOPHARMADIVE
In a first, FDA issues a serious rebuke for trial data delay
29 Apr 2021 //
FIERCE BIOTECH
FDA warns Acceleron of possible fines for not posting results from failed trial
29 Apr 2021 //
ENDPTS
Acceleron Announces Fourth Quarter and Full Year 2020 REBLOZYL® Net Sales
04 Feb 2021 //
BUSINESSWIRE
EC grants orphan status to Acceleron’s sotatercept to treat PAH
16 Dec 2020 //
PHARMABIZ
Acceleron Receives Orphan Designation from the (EC) for Sotatercept
14 Dec 2020 //
BUSINESSWIRE
Acceleron Receives Orphan Designation from the (EC) for Sotatercept
14 Dec 2020 //
BUSINESSWIRE
Acceleron Receives FDA Orphan Drug Designation for ACE-1334
01 Dec 2020 //
BUSINESSWIRE
Acceleron Presents New Data from the PULSAR Phase 2 Trial
13 Nov 2020 //
BUSINESSWIRE
Acceleron Announces Clinical Trial Updates, Preclinical on Sotatercept
09 Nov 2020 //
BIOSPACE
Acceleron Announces Clinical Trial , Preclinical Presentation on Sotatercept
09 Nov 2020 //
BUSINESSWIRE
Acceleron Announces REBLOZYL® (luspatercept-aamt) Virtual Presentations
04 Nov 2020 //
BUSINESSWIRE
Health Canada Approves REBLOZYL® (luspatercept)
29 Sep 2020 //
BUSINESSWIRE
Two Rare Disease Focused Biotechs Raise $900 Million in Follow-on Offerings
02 Jul 2020 //
GLOBALNEWS
